Are you a medical professional seeking the latest information on treating Irritable Bowel Syndrome (IBS)? Look no further than plecanatide, also known as Trulance - a promising new medication that has been shown to effectively relieve IBS symptoms. In this review of recent studies, we'll take a closer look at plecanatide and how it works, as well as any potential side effects you should be aware of. Keep reading to learn more about this exciting treatment option for your patients with IBS.
Plecanatide is a medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It belongs to a class of drugs called guanylate cyclase-C agonists, which stimulate the secretion of fluid in the intestines.
Unlike other medications that treat these conditions, plecanatide specifically targets the GC-C receptors found on intestinal cells. This selective targeting allows for more effective treatment with fewer side effects.
Plecanatide comes in tablet form and is taken orally once daily. The recommended dose for CIC is 3 mg per day, while the recommended dose for IBS-C is 1 mg per day.
Plecanatide offers an alternative option for those suffering from CIC and IBS-C. Its targeted approach can lead to effective relief without as many negative side effects commonly associated with traditional treatments.
Plecanatide is an FDA-approved medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It works by binding to the guanylate cyclase-C receptor located on the surface of intestinal cells.
When plecanatide binds to this receptor, it stimulates the production of cyclic guanosine monophosphate (cGMP), which promotes fluid secretion into the intestines. This increased fluid helps soften stool, making it easier to pass through the digestive tract.
Furthermore, plecanatide also reduces visceral hypersensitivity in people with IBS-C. Visceral hypersensitivity refers to a heightened sensitivity of internal organs such as the gut, leading to pain and discomfort associated with IBS symptoms like bloating and cramping.
By reducing visceral hypersensitivity, plecanatide can alleviate these uncomfortable symptoms for patients suffering from IBS-C. Plecanatide's mechanism of action provides relief for those who struggle with chronic constipation or IBS-C.
While plecanatide has shown to be effective in treating irritable bowel syndrome, it's important to consider the potential side effects. Like any medication, there can be some negative reactions that patients may experience.
Common side effects of plecanatide include diarrhea, abdominal pain, nausea and vomiting. These symptoms are typically mild to moderate in severity and will often improve over time as the patient continues with treatment.
Plecanatide is a promising treatment option for patients suffering from irritable bowel syndrome with constipation. It works by targeting the guanylate cyclase-C receptor and increasing fluid secretion in the intestines to promote regular bowel movements.
Recent studies have shown that plecanatide is effective in improving symptoms of IBS-C and has a favorable safety profile. However, as with any medication, there are potential side effects that should be carefully monitored.
Medical professionals can confidently consider prescribing plecanatide to their patients with IBS-C who have not responded well to other treatments or who experience bothersome side effects from current therapies.
The availability of plecanatide provides an important new tool for managing this common digestive disorder and improving quality of life for affected individuals.
1.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
2.
Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib
3.
In prostate cancer survivorship, sleep disturbances are underappreciated.
4.
Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer
5.
a cutting-edge cancer diagnostic tool.
1.
Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms
2.
Community Survivorship Networks for Long-Term Cancer Wellness
3.
Neuroendocrine Tumors: Case Study on Diagnosis, Treatment Strategies & Patient Management
4.
Targeted Therapies for Breast Cancer: What’s New?
5.
Integrated Insights in Hematology and Quality Improvement
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Hands-on Workshop: Hematology
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
5.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation